FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

NCPA Statement to FDA Compounding Session

The National Community Pharmacists Association raises several categories of concerns with FDA in advance of the agencys annual drug compounding listen...

Biologics

FDA Recognizes Blood Labeling Standard

FDA publishes a guidance recognizing the latest revision of the United States Industry Consensus Standard for the Uniform Labeling of Blood and Blood ...

latest-news-card-1
Federal Register

Final Rule on Lab-Developed Tests

Federal Register notice: FDA publishes a final rule to amend its regulations to make explicit that in vitro diagnostic products (IVDs) are devices und...

latest-news-card-1
Medical Devices

Multiple Pinnacle BioLabs Violations Seen

FDA warns Nashville, TN-based Pinnacle BioLabs that it is marketing and distributing a diagnostic test for an unapproved indication that also has Qual...

latest-news-card-1
Medical Devices

QS, MDR Violations at Future Diagnostics

FDA warns Gelderland, Netherlands-based Future Diagnostics Solutions about Quality System and Medical Device Reporting violations in its manufacturing...

latest-news-card-1
Human Drugs

FTC Expands Junk Patent Challenges

The Federal Trade Commission says it is expanding its challenges to junk drug patents with warnings to 10 companies about over 300 patent listings for...

latest-news-card-1
Human Drugs

Thiopurine Alert on Intrahepatic Cholestasis of Pregnancy

FDA issues a safety alert on the rare risk of intrahepatic cholestasis of pregnancy associated with the use of thiopurines (azathioprine, 6-mercaptopu...

Human Drugs

OND 55 Drug Approvals in 2023

The CDER Office of New Drugs says it participated in 55 novel drug approvals in 2023.

latest-news-card-1
Biologics

Pfizer Gets Traditional Approval for Tivdak

FDA gives Pfizer traditional approval for its previously accelerated-approved Tivdak (tisotumab vedotin-tftv) for recurrent or metastatic cervical can...

latest-news-card-1
Federal Register

Info Collection on FDA Recall Regs

Federal Register notice: FDA sends to OMB an information collection extension entitled FDA Recall Regulations 21 CFR Part 7.